Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson

Episode Summary

Executive Summary: Andrew Huberman and Dr. Matthew Johnson discuss what qualifies as a psychedelic, how classic psychedelics, ketamine, MDMA, and salvinorin A differ pharmacologically and experientially, and why therapeutic benefit likely depends on set, setting, and guided integration. They also cover microdosing skepticism, risks such as psychosis and bad trips, legal status, and emerging clinical uses for depression, PTSD, addiction, and possibly TBI.

Main Topics: What counts as a psychedelic (Priority: 5/5): Johnson explains that 'psychedelic' is a broad cultural term spanning multiple pharmacological classes, including classic serotonergic psychedelics, NMDA antagonists, salvinorin A, and MDMA, each with distinct receptor mechanisms and subjective effects. Mechanisms and altered self-representation (Priority: 5/5): The conversation centers on how psychedelics may disrupt predictive models of reality and self, producing hallucinations, synesthesia, and profound shifts in identity, agency, and perception. Therapeutic model: preparation, session, integration (Priority: 5/5): Johnson walks through the Hopkins clinical-trial model: screening, rapport-building, dosing in a safe container, and post-session integration to help translate the experience into lasting change. Microdosing versus macrodosing (Priority: 4/5): They examine claims that microdosing improves mood, focus, or creativity, but Johnson notes that controlled studies have not shown clear benefits and may show subtle impairment or placebo-driven effects. Risks, adverse effects, and flashbacks (Priority: 5/5): The discussion covers bad trips, cardiovascular monitoring, psychosis/bipolar risk, hallucinogen persisting perceptual disorder (HPPD), and why many 'flashback' reports are better explained by state-dependent learning or brief aftereffects. Legal status and regulation (Priority: 4/5): Johnson outlines the current U.S. legal landscape: psychedelics remain Schedule I federally, while state/local decriminalization varies; he argues future policy should emphasize regulation and training rather than prohibition or free-for-all access. Future applications: PTSD, addiction, and TBI (Priority: 4/5): Beyond depression, Johnson discusses promising but early-stage work on PTSD, substance use disorders, and possible neurorepair or cognitive benefits in traumatic brain injury and repetitive head-impact populations.

Key Arguments: Classic psychedelics (LSD, psilocybin, DMT, mescaline) are primarily 5-HT2A agonists/partial agonists, but the term 'psychedelic' also includes compounds like ketamine and MDMA because of overlapping subjective effects. The most important commonality across effective psychedelic therapies may be a durable change in self-representation rather than any single hallucination or mystical feature. Therapeutic outcomes depend heavily on preparation, a supportive environment, and integration afterward; the drug experience alone is not the treatment. Microdosing is widely discussed, but controlled studies have not demonstrated robust improvements in creativity, cognition, or mood; any benefits may be largely placebo or subtle antidepressant effects. Psychedelics can be destabilizing for people with psychotic disorders or bipolar mania, so careful screening is essential, especially in clinical research. Many 'flashbacks' are not true recurrent drug effects; they may reflect state-dependent learning, brief post-use perceptual changes, or rare HPPD. MDMA may be especially useful for trauma because it tends to produce less reality-shattering anxiety than classic psychedelics and may facilitate memory reprocessing. The field is moving from underground and anecdotal use toward regulated clinical science, with likely near-term approvals for specific indications if phase 3 results hold up.

Data Points: Psilocybin dose range in Hopkins studies: 5, 10, 20, and 30 mg (with 20–30 mg typically producing a psychedelic effect) - Dose-response work in healthy volunteers and therapeutic trials Psilocybin onset: ~15 minutes to 1 hour - Time from ingestion of capsule to noticeable effects Ketamine antidepressant duration: About 1 week - Spravato/S-ketamine effects described as rapid but relatively short-lived Preparation time before dosing: 4 to 8 hours - Therapeutic model includes extensive rapport-building before the session Integration session timing: Next day, 1 to 2 hours - Post-session discussion and processing after the psychedelic experience Bad-trip frequency at high-dose psilocybin: About 1/3 of participants - Even in well-prepared, controlled Hopkins sessions at ~30 mg LSD microdose threshold discussed: ~10–20 micrograms - Johnson contrasts this with a psychedelic dose around 100 micrograms LSD psychedelic threshold: ~100 micrograms - Entry-level psychedelic effects for LSD Center funding: $17 million - Gift that helped establish Hopkins' psychedelic center Funding split: 50/50 - Gift divided between the Cohen Foundation and the Tim Ferriss Collaborative Psilocybin species count: Over 200 species - Johnson notes psilocybin occurs in many mushroom species DMT plant sources: Dozens and dozens of plants - Used to illustrate broad natural occurrence of DMT HPPD prevalence: Very small number of users - Rare persistent perceptual disorder after hallucinogen use

Pivotal Quotes: "they all had the ability to profoundly alter one's sense of reality" — Dr. Matthew Johnson: Defining psychedelics across different pharmacological classes "the common denominator are persisting changes in self-representation" — Dr. Matthew Johnson: Explaining what may underlie therapeutic effects across different psychedelic experiences "Plasticity is never the goal. Goal-directed plasticity is the goal" — Andrew Huberman: Discussing why experience-driven change must be directed rather than indiscriminate

Implications: The episode frames psychedelics as promising but powerful tools that require careful screening, guided use, and integration. It suggests near-term medical approvals are plausible, but broad public access should come with regulation, training, and more evidence.